AGN-241622 + Vehicle
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia
Trial Timeline
Jul 27, 2020 → Dec 5, 2022
NCT ID
NCT04403763About AGN-241622 + Vehicle
AGN-241622 + Vehicle is a phase 1/2 stage product being developed by AbbVie for Presbyopia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04403763. Target conditions include Presbyopia.
What happened to similar drugs?
1 of 6 similar drugs in Presbyopia were approved
Approved (1) Terminated (1) Active (5)
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic SolutionLENZ TherapeuticsPhase 3
🔄Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehicleLENZ TherapeuticsPhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04403763 | Phase 1/2 | Terminated |
Competing Products
14 competing products in Presbyopia